TLR9 and B-cell chronic lymphocytic leukemia: In CD40-stimulated CLL cells of ibrutinib-treated patients, TLR9 stimulation via CpG led to increased venetoclax resistance (p < 0.05), almost to the same extent as observed at baseline (N = 5) (Fig. 7C).